Understanding and managing the possible adverse effects associated with bevacizumab
- 1 June 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 66 (11), 999-1013
- https://doi.org/10.2146/ajhp080455
Abstract
Purpose. The adverse events associated with bevacizumab therapy are characterized, and the underlying pathophysiology, risk factors, frequency, and management of these events are described. Summary. The adverse events associated with bevacizumab include hypertension, proteinuria, thromboembolism, impaired wound healing, bleeding, perforation, reversible leukoencephalopathy syndrome, skin rash, and infusion-related hypersensitivity reactions. Patients should be monitored for these events throughout the course of bevacizumab therapy. Hypertension is by far the most common adverse event associated with bevacizumab. Blood pressure should be routinely monitored, and hypertension should be medically managed with antihypertensive drugs as deemed appropriate during bevacizumab therapy. Patients should be monitored for proteinuria every three to four weeks, and bevacizumab should be discontinued with persistent proteinuria of >2+. Thromboembolic events, impaired wound healing, bowel and nasal septum perforation, and bleeding share similar pathophysiology. Thromboembolic events should be managed in accordance with guidelines established by the American College of Chest Physicians, and bevacizumab should be discontinued for new life-threatening venous or arterial thromboembolism. To minimize the risk of bleeding or impaired wound healing, bevacizumab should be started at least four weeks after surgery or discontinued for at least six to eight weeks before elective surgery. The management of other adverse events is more anecdotal, with relatively few reports of their occurrence with bevacizumab. Conclusion. Many of the potential serious complications of bevacizumab can be averted by close monitoring of patient- specific variables, which should be measured at baseline and then at predetermined intervals throughout the course of therapy to maximize patient safety.Keywords
This publication has 92 references indexed in Scilit:
- Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculationAnnals Of Oncology, 2007
- Vascular endothelial growth factor: Biology and therapeutic applicationsThe International Journal of Biochemistry & Cell Biology, 2007
- Mechanisms of adverse effects of anti-VEGF therapy for cancerBritish Journal of Cancer, 2007
- Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-AnalysisAmerican Journal of Kidney Diseases, 2007
- Phase II Multicenter Trial of Bevacizumab Plus Fluorouracil and Leucovorin in Patients With Advanced Refractory Colorectal Cancer: An NCI Treatment Referral Center Trial TRC-0301Journal of Clinical Oncology, 2006
- Mechanisms of Hypertension Associated With BAY 43-9006Journal of Clinical Oncology, 2006
- Bevacizumab: An Angiogenesis Inhibitor with Efficacy in Colorectal and Other MalignanciesAnnals of Pharmacotherapy, 2004
- Angiogenic growth factors and hypertensionAngiogenesis, 2004
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003
- Vascular Endothelial Growth Factor/Vascular Permeability Factor Produces Nitric Oxide–Dependent HypotensionArteriosclerosis, Thrombosis, and Vascular Biology, 1997